NDEP updates website with new videos
WASHINGTON — The Department of Health and Human Services’ National Diabetes Education Program has unveiled a series of videos designed to help people make lifestyle changes and cope with the demands of diabetes.
The NDEP said the three- to five-minute videos, which can be accessed at YourDiabetesInfo.org/HealthSense, address such topics as setting goals to improve health, living with diabetes and finding the support you need, as well as segments on diabetes prevention and physical activity. The launch of the videos coincides with the redesign of the NDEP’s online library of behavior change resources.
“For more than 14 years, the NDEP has been [at] the forefront of raising awareness about diabetes, but more needs to be done to provide resources and tools to support healthcare providers and their patients when it comes to achieving and sustaining health goals,” said Griffin Rodgers, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, one of the sponsors of NDEP.
The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention.
Pfizer, Acura get FDA OK for Oxecta
NEW YORK — The Food and Drug Administration has approved a medication designed to treat acute and chronic moderate to severe pain, where the use of an opioid analgesic is suitable.
Pfizer and Acura Pharmaceuticals said that their drug Oxecta (oxycodone HCl, USP tablets) is the first tamper-resistant medication designed to deter abuse and misuse with Aversion technology, which is being licensed by Pfizer from Acura.
Opioid medications are an important treatment option for patients with moderate to severe pain who are not adequately managed by other pain treatments, Pfizer and Acura said, noting that abuse and misuse of opioids is a serious public health issue.
"We are excited to be partnered with Pfizer to bring Oxecta to patients who need opioids to manage their pain," Acura’s interim president and CEO Robert Jones said. "Acura is focused on developing technologies that are intended to potentially deter abuse and misuse."
ProStrakan receives FDA approval to market Rectiv
GALASHIELS, Scotland, and BEDMINSTER, N.J. — ProStrakan has received approval from the Food and Drug Administration to market an ointment designed to treat moderate to severe pain associated with chronic anal fissures.
The drug maker, which is a subsidiary of Kyowa Hakko Kirin, said that it received regulatory approval for Rectiv (nitroglycerin) ointment 0.4%. Rectiv currently is the only FDA-approved prescription product for patients with this condition. ProStrakan expects Rectiv to be available in the United States in first quarter 2012.
Approximately 700,000 people in the United States receive a diagnosis or treatment for anal fissures each year. An anal fissure is a small tear in the skin that lines the anus and can occur in a number of ways, such as passing large or hard stools, straining during a bowel movement or following an episode of diarrhea. When an anal fissure occurs, it typically causes severe pain and bleeding with bowel movements.
The product is marketed under the name Rectogesic in the European Union and already is approved in the EU and marketed by ProStrakan in all major European countries.